
浏览全部资源
扫码关注微信
目的:为药品生产企业数据完整性管理体系的完善提供参考。方法:根据美国FDA与国家食品药品监督管理总局的相关报道,分析数据完整性问题来源,归纳数据完整性问题的原因并提出解决措施。结果与结论:企业出现数据完整性问题的原因可归结于员工、硬件/软件系统和质量管理体系三方面,各方面与现行标准存在较大差距。建议企业采取差距分析的方法评估现有体系,组建数据完整性管理项目团队并加强人员培训,升级硬件/软件系统保证其安全性、稳定性和有效性,通过建立良好文件规范、数据完整性专项监管体系来优化质量管理体系;此外,企业应建立质量文化、实时关注行业与法规动态,以有效保证数据的完整性。
OBJECTIVE: To provide reference for improving the data integrity management system of pharmaceutical production enterprises. METHODS: According to related reports in US Food and Drug Administration (FDA) and China Food and Drug Administration (CFDA), the source of data integrity problems was analyzed, its reasons were summarized and solutions were put forward. RESULTS & CONCLUSIONS: The reasons why there were data integrity problems in enterprises can be attributed to 3 aspects (staff, hardware/software system and quality management), and the 3 aspects showed large gap with current standards. It is suggested that enterprises evaluate the existing system by adopting the gap analysis, establish a data integrity management project team, strengthen personnel training, upgrade hardware/software system to ensure its safety, stability and effectiveness; and optimize the quality management system by developing good ducument specification, special regulation system of data integrity. In addition, the enterprise should establish quality culture, pay attention to industry and regulatory trends in real time to guarantee the data integrity effectively.
药品生产企业数据完整性员工硬件软件质量管理体系
Pharmaceutical production enterpriseData integrityStaffHardwareSoftwareQuality management system
0
浏览量
9
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
公网安备50010302001817